---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-047085"
form_type: "8-K"
ticker: "GTBP"
cik: "0000109657"
company_name: "GT Biopharma, Inc."
filed_at: "2024-11-21T23:59:59+00:00"
generated_at: "2026-05-29T20:22:06.216547+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# GT Biopharma enters Phase 1 clinical trial agreement with U of Minnesota for GTB-3650 in MDS/AML

## Summary
- Agreement for investigator-initiated Phase 1 trial of GTB-3650 (CD16/IL-15/CD33 TriKE) in high-risk MDS, relapsed/refractory AML, MRD.
- Budget up to ~$2 million over three years, funded entirely by GT Biopharma.
- University of Minnesota sponsors the IND and acts as sponsor-investigator; Company supplies study drug and funding.
- Study data owned by University; Company may use data subject to consent and laws; each party may publish results.
- Agreement terminable on 30 days' notice by either party, or immediately for safety reasons.

## SEC filing metadata
- accession: 0001493152-24-047085
- form_type: 8-K
- ticker: GTBP
- cik: 0000109657
- company_name: GT Biopharma, Inc.
- filed_at: 2024-11-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/0001493152-24-047085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/109657/000149315224047085/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-047085
- JSON: https://secwatch.observer/filing/0001493152-24-047085.json
- Plain text: https://secwatch.observer/filing/0001493152-24-047085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.